GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
B

Bright Minds Biosciences DRUG · USD

Health Care · US listing · 🇺🇸 United States

Compare

24.11

+4.83%

Close of 9 Nov 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in USD, from our data supplier.

FY2025

Net income

−$8.9m

FY2019FY2025

Free cash flow

−$6.3m

FY2019FY2025

Shareholders' equity

$59.5m

FY2019FY2025

Income statement

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019
Gross profit−$55,848—−$52,564−$4,380———
Research and development$8.0m$856,120$3.6m$8.8m$4.6m$257,452$91,435
Operating income−$10.1m−$2.0m−$5.4m−$10.9m−$6.4m−$340,528−$171,332
Net income−$8.9m−$2.0m−$5.3m−$10.9m−$6.2m−$352,563−$171,332
Diluted earnings per share-1.14-0.44-1.39-3.03-2.61-0.30-0.15

Balance sheet

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019
Total assets$61.2m$4.4m$5.0m$8.8m$14.5m$638,614$118,964
Cash and short-term investments$60.2m$4.2m$4.9m$8.4m$14.3m$580,364$58,035
Total liabilities$1.7m$412,283$203,767$1.1m$463,297$109,498$26,632
Debt$61,327$57,595$53,361$49,283———
Shareholders' equity$59.5m$4.0m$4.8m$7.6m$14.1m$529,116$92,331
Shares outstanding8m5m4m4m2m1m1m

Cash flow

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019
Cash from operations−$6.3m−$1.3m−$5.1m−$9.9m−$5.3m−$209,234−$30,478
Capital spending——−$4————
Free cash flow−$6.3m−$1.3m−$5.1m−$9.9m−$5.3m−$209,234−$30,478

Latest quarters

By quarter end

Jun 2026Mar 2026Dec 2025Sept 2025Jun 2025Mar 2025Dec 2024Sept 2024
Gross profit−$14,491−$14,605−$14,345−$8,860−$8,444———
Operating income−$8.5m−$11.3m−$5.0m−$4.1m−$2.4m−$2.4m−$1.2m−$574,111
Net income−$1.8m−$7.7m−$5.5m−$3.0m−$3.8m−$2.1m$35,993−$561,147
Diluted earnings per share-0.18-0.78-0.71-0.38-0.49-0.280.01-0.12
Cash from operations−$6.0m−$6.0m−$4.0m—−$2.0m−$1.0m−$1.0m—
Total assets$225.5m$226.5m$65.9m$61.2m$38.1m$41.0m$42.4m$4.4m
Cash and short-term investments$223.7m$224.5m$64.6m$60.2m$37.3m$40.4m$42.0m$4.2m
Debt$47,664$59,587$63,959$61,327$56,727$56,409$52,720$57,595
Shareholders' equity$223.7m$223.7m$64.8m$59.5m$37.6m$40.4m$42.0m$4.0m

Growth per year

Compound annual rate

3 years5 years10 years
Operating income-2.4%97.0%—
Net income-6.5%90.6%—

Valuation history

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021
Price to earnings-32.5-39.3-0.5-0.6-2.9

Share price return

Finished calendar years

20252024202320222021
Return107%2487%-68%-73%-37%

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.